Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Citigroup Inc.

Citigroup Inc. reduced its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) by 39.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,934 shares of the company’s stock after selling 66,881 shares during the period. Citigroup Inc. owned approximately 0.18% of Zentalis Pharmaceuticals worth $2,053,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Captrust Financial Advisors raised its holdings in shares of Zentalis Pharmaceuticals by 15,160.0% during the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock worth $35,000 after purchasing an additional 758 shares during the last quarter. Great West Life Assurance Co. Can purchased a new position in Zentalis Pharmaceuticals in the third quarter valued at $48,000. Point72 Hong Kong Ltd purchased a new position in Zentalis Pharmaceuticals in the third quarter valued at $59,000. Metropolitan Life Insurance Co NY increased its holdings in Zentalis Pharmaceuticals by 24.1% in the third quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company’s stock valued at $61,000 after buying an additional 550 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Zentalis Pharmaceuticals by 378.9% in the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock valued at $67,000 after buying an additional 1,148 shares in the last quarter.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $27.16 on Friday. Zentalis Pharmaceuticals, Inc. has a twelve month low of $15.55 and a twelve month high of $32.34. The firm’s 50-day moving average price is $21.12 and its 200 day moving average price is $20.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last posted its quarterly earnings results on Wednesday, May 10th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.11). As a group, sell-side analysts predict that Zentalis Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

ZNTL has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $55.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 2nd. Stifel Nicolaus dropped their target price on shares of Zentalis Pharmaceuticals from $46.00 to $45.00 in a research report on Thursday, May 11th. Finally, Jefferies Financial Group dropped their target price on shares of Zentalis Pharmaceuticals from $120.00 to $70.00 in a research report on Friday, May 19th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $46.00.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.